Elios Therapeutics announced positive top-line results from the prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial evaluating its lead immuno-oncology candidate, TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with stage 3 and 4 resected melanoma.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
